Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Gynecol Cancer ; 34(6): 906-918, 2024 Jun 03.
Artigo em Inglês | MEDLINE | ID: mdl-38658022

RESUMO

OBJECTIVES: Circulating tumor DNA (ctDNA) is emerging as a potential prognostic biomarker in multiple tumor types. However, despite the many studies available on small series of patients with ovarian cancer, a recent systematic review and meta-analysis is lacking. The objective of this study was to determine the association of ctDNA with progression-free-survival and overall survival in patients with epithelial ovarian cancer. METHODS: An electronic search was conducted using PubMed (MEDLINE), Embase, CENTRAL (Cochrane Library), and CINAHL-Complete from January 2000 to September 15, 2023. To be included in the analysis the studies had to meet the following pre-specified inclusion criteria: (1) evaluable ctDNA; (2) progression-free-survival and overall survival reported as hazard ratio (HR); and (3) the patient population had epithelial ovarian cancer at the time of ctDNA detection. We evaluated the association of ctDNA with progression-free survival and overall survival. Secondary outcomes focused on sub-group analysis of genomic alterations and international Federation of Gynecology and Obstetrics (FIGO) stage. RESULTS: A total of 26 studies reporting on 1696 patients with epithelial ovarian cancer were included. The overall concordance rate between plasma-based and tissue-based analyses was approximately 62%. We found that a high level of ctDNA in epithelial ovarian cancer was associated with worse progression-free survival (HR 5.31, 95% CI 2.14 to 13.17, p<0.001) and overall survival (HR 2.98, 95% CI 1.86 to 4.76, p<0.0001). The sub-group analysis showed a greater than threefold increase in the risk of relapse in patients with positive HOXA9 meth-ctDNA (HR 3.84, 95% CI 1.57 to 9.41, p=0.003). CONCLUSIONS: ctDNA was significantly associated with worse progression-free survival and overall survival in patients with epithelial ovarian cancer. Further prospective studies are needed. PROSPERO REGISTRATION NUMBER: CRD42023469390.


Assuntos
Biomarcadores Tumorais , Carcinoma Epitelial do Ovário , DNA Tumoral Circulante , Neoplasias Ovarianas , Intervalo Livre de Progressão , Humanos , Feminino , Carcinoma Epitelial do Ovário/mortalidade , Carcinoma Epitelial do Ovário/sangue , Carcinoma Epitelial do Ovário/genética , Carcinoma Epitelial do Ovário/patologia , DNA Tumoral Circulante/sangue , DNA Tumoral Circulante/genética , Neoplasias Ovarianas/sangue , Neoplasias Ovarianas/mortalidade , Neoplasias Ovarianas/genética , Neoplasias Ovarianas/patologia , Biomarcadores Tumorais/sangue , Biomarcadores Tumorais/genética
2.
J Clin Med ; 13(8)2024 Apr 11.
Artigo em Inglês | MEDLINE | ID: mdl-38673471

RESUMO

Hypertensive disorders of pregnancy (HDP) and gestational diabetes mellitus (GDM) are the most common medical complications in pregnancy. Physical exercise is considered to be safe and beneficial during pregnancy. Moreover, pregnancy could be considered as an opportunity for healthcare providers to promote positive lifestyle behavior and optimize the well-being of pregnant women. Since there are few up-to-date reviews evaluating the role of exercise and the risks of developing obstetrical complications, we performed a review to investigate the effects of physical activity and exercise during pregnancy compared to a control group, focusing on the risk of development of HDP and GDM. We searched Medline and Web of Science, including only randomized controlled trials (RCTs) and systematic reviews. This review supports a beneficial effect of exercise and provides evidence that it significantly decreases the risk of HDP and GDM.

3.
Eur J Obstet Gynecol Reprod Biol ; 289: 108-128, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37660506

RESUMO

OBJECTIVE: Pharmacological agents such as prostaglandins (dinoprostone and misoprostol) are commonly used to reduce the duration of labor and promote vaginal delivery. However, key safety considerations with its use include an increased risk of uterine rupture, tachysystole and hyperstimulation of pregnant women, which could potentially lead to a non-reassuring fetal heart rate and to fetal hypoxemia. The aim of this systematic review was to assess maternal and fetal outcomes between misoprostol group (PGE1) and dinoprostone group (PGE2) STUDY DESIGN: We search on MEDLINE (PubMed), CINHAL (EBSCOhost), EMBASE, Scopus (Ovid), CENTRAL (January 1, 1998, to December 31, 2022). Patients were eligible if they presented at greater than 36 weeks gestation with an indication for induction of labor and a single live cephalic fetus. We conducted a meta-analysis of data for both primary (cesarean section rate, instrumental deliveries rate, tachysystole, uterine rupture, post-partum haemorrage; chorionamiositis) and secondary outcomes (Apgar at 5 min <7, meconium-stained liquor, NICU admission, infant death) using odds-ratio (OR) as a measure of effect-size. Risk of bias assessment was performed with RoB-I. We performed statistical analyses using Cochrane RevMan version 5.4 software. RESULTS: We found 39 RCTs comparing the outcomes of interest between misoprostol and dinoprostone. The pooled effect showed no statistically significant difference between the two groups in terms of cesarean section rate [OR: 0.94; 95% CI 0.84-1.05], instrumental deliveries rate [OR: 1.04; 95% CI: 0.90-1.19; p = 0.62], tachysystole [OR: 1.21; 95% CI: 0.91-1.60; p = 0.19], post-partum hemorrhage [OR: 0.85; 95% CI: 0.62-1.15p = 0.30], chorioamnionitis [OR: 0.94; 95% CI: 0.76-1.17p = 0.59], Apgar at 5 min < 7 [OR: 0.83; 95% CI: 0.61-1.12, p = 0.21], meconium-stained liquor [OR: 1.11; 95% CI: 0.97-1.27p = 0.59], NICU admission group [OR: 0.91; 95% CI: 0.77-1.09], infant death [OR: 0.57; 95% CI: 0.22-1.44]. After performing a sub-group analysis based on the type of prostaglandins administrations (oral, vaginal gel, vaginal pessary), results did not change substantially. CONCLUSIONS: This systematic review and meta-analysis demonstrate that misoprostol and dinoprostone appear to have a similar safety profile.


Assuntos
Abortivos não Esteroides , Misoprostol , Ocitócicos , Ruptura Uterina , Lactente , Humanos , Feminino , Gravidez , Dinoprostona/efeitos adversos , Misoprostol/efeitos adversos , Cesárea , Prostaglandinas , Ocitócicos/efeitos adversos , Morte do Lactente , Trabalho de Parto Induzido/efeitos adversos
4.
BJOG ; 130(4): 348-357, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36444098

RESUMO

BACKGROUND: There are limited data regarding COVID-19 vaccination during pregnancy. OBJECTIVES: To evaluate the effects of COVID-19 vaccination received during pregnancy on SARS-CoV-2 infection, COVID-19-related hospitalisation, COVID-19-related intensive care unit (ICU) admission and maternal-fetal complications. SEARCH STRATEGY: MEDLINE, CINHAL, Embase, Scopus and CENTRAL databases, as well as ClinicalTrials.gov, reference lists, related articles and grey literature sources. SELECTION CRITERIA: Randomised controlled trials, non-randomised studies of interventions, pregnant women, COVID-19 vaccination during pregnancy. DATA COLLECTION AND ANALYSIS: Study selection, risk-of-bias assessment, data extraction and assessment of the certainty of evidence using the GRADE method were performed independently by two authors. Meta-analyses were performed using Cochrane RevMan 5.4. PROSPERO registration number: CRD42022308849. MAIN RESULTS: We included 14 observational studies (362 353 women). The administration of a COVID-19 vaccine during pregnancy resulted in a statistically significant reduction in SARS-CoV-2 infection (OR 0.46, 95% CI 0.28-0.76) and COVID-19-related hospitalisation (OR 0.41, 95% CI 0.33-0.51). The effect appeared to be greater in fully vaccinated women, for both infection (OR 0.31, 95% CI 0.16-0.59) and hospitalisation (OR 0.15, 95% CI 0.10-0.21). However, the certainty of evidence was very low. The difference in COVID-19-related ICU admission between vaccinated and unvaccinated individuals did not reach statistical significance (OR 0.58, 95% CI 0.13-2.58). Finally, there were no statistically significant differences in any of the maternal-fetal complications considered in the included studies. CONCLUSIONS: COVID-19 vaccination administered during pregnancy seems to reduce SARS-CoV-2 infection and COVID-19-related hospitalisation, with no significant effects on maternal-fetal complications.


Assuntos
Vacinas contra COVID-19 , COVID-19 , Gestantes , Feminino , Humanos , Gravidez , COVID-19/epidemiologia , COVID-19/prevenção & controle , Vacinas contra COVID-19/efeitos adversos , Unidades de Terapia Intensiva , SARS-CoV-2
5.
J Matern Fetal Neonatal Med ; 35(25): 9006-9013, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34882044

RESUMO

OBJECTIVES: To evaluate the association between ultrasound measured angle of progression (AoP) during labor and time to delivery (TTD) or second stage of labor duration (SSLD). METHODS: This systematic review (SR) was reported according to PRISMA statement 2020. Databases investigated were MEDLINE, CINHAL, Embase, Scopus, Web of Science. Other sources were references or related articles of included studies, Google Scholar, clinicaltrials.gov, thesis, expert groups. Main keywords: angle of progression, transperineal ultrasound, delivery, labor. Inclusion criteria were observational studies, single term pregnancy, cephalic presentation, AoP measurement during the first stage of labor or at the beginning of the second stage, without date restrictions. Language included: English, Italian, French, Spanish. Studies selection, evaluation of the risk of bias with Quality in Prognosis Studies (QUIPS) tool, and data extraction were carried out by two authors blindly and independently, with disagreement resolution by a third author. Qualitative summary of the results. This SR was registered on PROSPERO, number CDR42021232015. RESULTS: Of 428 records, 14 were included, published from 2009 to 2021, cumulatively analyzing 2498 women. All studies highlighted an inverse relationship between AoP and TTD. Some have identified an AoP cutoff, contained in a range between 110° and 129°, beyond which the duration of labor is significantly shorter. Others, a range between 137° and 160°, beyond which the duration of the expulsive period is significantly shorter. Finally, some factors influence this association: parity, epidural, and oxytocin. CONCLUSIONS: This SR confirms a significant association between AoP in labor and TTD. In clinical practice, AoP could help to predict the duration of labor, facilitating decision-making. The main limitations of this SR were the low number of included studies, their heterogeneity, and the high risk of bias related to confounding factors. For future research, further studies are needed to increase the strength of the evidence, obtain stratified results according to patients' characteristics and investigate groups of patients who have not yet been evaluated.


Assuntos
Segunda Fase do Trabalho de Parto , Ultrassonografia Pré-Natal , Humanos , Gravidez , Feminino , Ultrassonografia Pré-Natal/métodos , Estudos Prospectivos , Paridade , Ultrassonografia/métodos , Apresentação no Trabalho de Parto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...